Lurasidone Potential for serious and/or life-threatening reactions Ergot derivatives Ergotamine, ergot toxicity characterised by vasospasm dihydroergotamine, and tissue ischemia has been associated with ergonovine, of ritonavir and ergonovine, methylergonovine ergotamine, dihydroergotamine, or methylergonovine. Ethinyl Potential for ALT elevations [see Precautions]. products medications such as combined oral contraceptives GI motility agent Cisapride Potential for cardiac arrhythmias. Herbal product St. John’s Wort Ombitasvir, paritaprevir and ritonavir exposures (Hypericum may decrease leading to a potential loss of perforatum) therapeutic activity of TECHNIVIE. Lovastatin, Potential for myopathy including HMG-CoA reductase simvastatin, rhabdomyolysis. inhibitors atorvastatin Long acting Salmeterol The combination may result in increased risk of agonist cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. Neuroleptics Pimozide Potential for cardiac arrhythmias. Non-nucleoside reverse Efavirenz Co-administration of efavirenz based regimens transcriptase inhibitor with paritaprevir and ritonavir was poorly tolerated and resulted in liver enzyme elevations. Phosphodiesterase-5 Sildenafil when as There is increased potential for (PDE5) inhibitor REVATIO for the adverse events such as visual treatment of disturbances, hypotension, priapism, and pulmonary arterial syncope. hypertension (PAH) Platelet aggregation Ticagrelor Increased potential for ticagrelor associated inhibitors excluding adverse events. heparin
Lurasidone Potential for serious and/or life-threatening reactions Ergot derivatives Ergotamine, dihydroergotamine, ergonovine, methylergonovine ergot toxicity characterised by vasospasm and tissue ischemia has been associated with of ritonavir and ergonovine, ergotamine, dihydroergotamine, or methylergonovine. products Ethinyl medications such as combined oral contraceptives Potential for ALT elevations [see Precautions]. GI motility agent Cisapride Potential for cardiac arrhythmias. Herbal product St. John’s Wort (Hypericum perforatum) Ombitasvir, paritaprevir and ritonavir exposures may decrease leading to a potential loss of therapeutic activity of TECHNIVIE. HMG-CoA reductase inhibitors Lovastatin, simvastatin, atorvastatin Potential for myopathy including rhabdomyolysis. Long acting agonist Salmeterol The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. Neuroleptics Pimozide Potential for cardiac arrhythmias. Non-nucleoside reverse transcriptase inhibitor Efavirenz Co-administration of efavirenz based regimens with paritaprevir and ritonavir was poorly tolerated and resulted in liver enzyme elevations. Phosphodiesterase-5 (PDE5) inhibitor Sildenafil when as REVATIO for the treatment of pulmonary arterial hypertension (PAH) There is increased potential for adverse events such as visual disturbances, hypotension, priapism, and syncope. Platelet aggregation inhibitors excluding heparin Ticagrelor Increased potential for ticagrelor associated adverse events.
auspar-paritaprevir-ritonavir-ombitasvir-171005-pi.docx